Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Scios
Scios
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Natrecor
Nesiritide
2001-08-10
Paroxysmal dyspnea
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Nesiritide
diastolic heart failure
,
heart transplantation
,
acute kidney injury
,
left ventricular dysfunction
,
cardiopulmonary bypass
,
coronary disease
,
coronary artery disease
,
myocardial ischemia
,
coronary artery bypass
,
heart diseases
,
paroxysmal dyspnea
,
acute coronary syndrome
,
kidney diseases
,
heart failure
,
cardiomyopathies
,
renal insufficiency
,
dyspnea
,
pulmonary edema
,
hypertension
,
dilated cardiomyopathy
Enoblituzumab
surgical wound
Sodium chloride
healthy volunteers/patients
,
thrombocytosis
,
inflammatory bowel diseases
,
deficiency diseases
,
ulcerative colitis
,
crohn disease
,
colitis
,
intestinal diseases
,
systolic heart failure
,
iron deficiencies
,
iron-deficiency anemia
,
anemia
,
heart failure
,
fatigue
,
hemorrhage
,
orthopedic procedures
,
postoperative complications
,
coronary artery disease
,
aortic valve stenosis
,
mitral valve insufficiency
,
thoracic aortic aneurysm
,
aortic aneurysm
,
hypertension
,
pulmonary arterial hypertension
,
familial primary pulmonary hypertension
,
pregnancy complications
TALMAPIMOD
rheumatoid arthritis
,
arthritis
,
multiple myeloma
,
plasma cell neoplasms
,
myelodysplastic syndromes
,
hematologic diseases
,
preleukemia
,
bone marrow diseases
,
syndrome
,
bone marrow neoplasms
Hidroxicloroquina
prostatic neoplasms
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use